Video Experimental Relacionado

Updated: Oct 17, 2025

Photoactivated Localization Microscopy with Bimolecular Fluorescence Complementation BiFC-PALM

Photoactivated Localization Microscopy with Bimolecular Fluorescence Complementation BiFC-PALM

Published on: December 22, 2015

Cumplimiento de las GAP en la comprensión de RAS

Adrienne D Cox^1,2,3, Channing J Der^1,3

¹Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA.

Science (New York, N.Y.)

|October 7, 2021

Resumen

Un regulador recientemente descubierto mejora la eficacia de los nuevos fármacos anti-RAS dirigidos. Este hallazgo ofrece una estrategia prometedora para mejorar los resultados de la terapia del cáncer.

Área de la Ciencia:

En el campo de la oncología
Biología molecular
Descubrimiento de drogas

Sus antecedentes:

Las proteínas RAS son factores clave en muchos cánceres.
Las terapias dirigidas contra el RAS son un área de investigación activa.
La mejora de la eficacia de estas terapias es crucial para los resultados de los pacientes.

Objetivo del estudio:

Identificar nuevos reguladores que pueden mejorar la eficacia de los fármacos anti-RAS dirigidos.
Investigar el mecanismo por el cual este regulador afecta la respuesta al fármaco.

Principales métodos:

Se utilizó el cribado genético para identificar posibles reguladores.
Se han realizado experimentos in vitro e in vivo para validar los hallazgos.
Análisis de las vías moleculares afectadas por el regulador y el tratamiento farmacológico.

Principales resultados:

Se identificó un nuevo regulador que aumenta significativamente la eficacia de una nueva clase de fármacos anti-RAS dirigidos.
Se demostró que el regulador modula las vías de señalización clave involucradas en los cánceres impulsados por RAS.
La terapia combinada con el regulador y los fármacos anti-RAS demostró una mayor inhibición del crecimiento tumoral.

Conclusiones:

El regulador recién identificado representa un objetivo terapéutico prometedor para mejorar la eficacia de los medicamentos anti-RAS.
Este descubrimiento abre nuevas vías para el desarrollo de estrategias de combinación en oncología.
Se requieren más estudios clínicos para explorar el potencial terapéutico.

Más Videos Relacionados

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

Videos de Conceptos Relacionados

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Small GTPases - Ras and Rho

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Rab Cascades

Rab Cascades

Rab GTPases act in a regulated cascade during membrane fusion, helping the lipid bilayers mix. The Rab family of proteins are active when bound to GTP, and inactive when bound to GDP. Hence, they act as guanine nucleotide-dependent molecular switches. Rab-GTP recognizes and binds to long or short-range tethering proteins to capture the target vesicle. These tethers coordinate with SNAREs on the vesicle and the target membrane to assemble the trans SNARE complex that locks the mixing bilayers.

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Rab Proteins

Rab Proteins

Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...